Anna Jaźwińska-Curyłło

Combined therapy with CD4+CD25highCD127− T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial

W. Młynarski, J. Siebert, A. Bossowski, 2022, Diabetes, obesity & metabolism.

Proinsulin-specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy

W. Młynarski, J. Siebert, A. Bossowski, 2020, BMJ Open Diabetes Research & Care.

Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes

W. Młynarski, P. Witkowski, J. Siebert, 2016, Journal of Translational Medicine.

Assessment of anti‐SARS‐CoV‐2 antibodies level in convalescents plasma

W. Narożny, A. Skorek, D. Tretiakow, 2021, Journal of medical virology.

Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study

W. Nyka, P. Trzonkowski, E. Szurowska, 2021, BioDrugs.

Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study

W. Nyka, P. Trzonkowski, E. Szurowska, 2021, BioDrugs.

Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes

W. Młynarski, P. Witkowski, J. Siebert, 2016, Journal of Translational Medicine.

Correlation of ENT Symptoms with Age, Sex, and Anti-SARS-CoV-2 Antibody Titer in Plasma

A. Skorek, P. Burduk, D. Tretiakow, 2023, Journal of clinical medicine.